Current therapeutic strategies and novel approaches in osteosarcoma - PubMed (original) (raw)

Current therapeutic strategies and novel approaches in osteosarcoma

Kosei Ando et al. Cancers (Basel). 2013.

Abstract

Osteosarcoma is the most frequent malignant primary bone tumor and a main cause of cancer-related death in children and adolescents. Although long-term survival in localized osteosarcoma has improved to about 60% during the 1960s and 1970s, long-term survival in both localized and metastatic osteosarcoma has stagnated in the past several decades. Thus, current conventional therapy consists of multi-agent chemotherapy, surgery and radiation, which is not fully adequate for osteosarcoma treatment. Innovative drugs and approaches are needed to further improve outcome in osteosarcoma patients. This review describes the current management of osteosarcoma as well as potential new therapies.

PubMed Disclaimer

Figures

Figure 1

Five year overall survival of localized osteosarcoma (from Allison et al. [9]).

Similar articles

• Therapy for osteosarcoma: where do we go from here?
  Chou AJ, Geller DS, Gorlick R. Chou AJ, et al. Paediatr Drugs. 2008;10(5):315-27. doi: 10.2165/00148581-200810050-00005. Paediatr Drugs. 2008. PMID: 18754698 Review.
• Therapeutic Potential of Circular RNAs in Osteosarcoma.
  Wan B, Hu H, Wang R, Liu W, Chen D. Wan B, et al. Front Oncol. 2020 Apr 15;10:370. doi: 10.3389/fonc.2020.00370. eCollection 2020. Front Oncol. 2020. PMID: 32351876 Free PMC article. Review.
• Mechanisms of Resistance to Conventional Therapies for Osteosarcoma.
  Marchandet L, Lallier M, Charrier C, Baud'huin M, Ory B, Lamoureux F. Marchandet L, et al. Cancers (Basel). 2021 Feb 8;13(4):683. doi: 10.3390/cancers13040683. Cancers (Basel). 2021. PMID: 33567616 Free PMC article. Review.
• Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression.
  Fan TM, Roberts RD, Lizardo MM. Fan TM, et al. Front Oncol. 2020 Jan 31;10:13. doi: 10.3389/fonc.2020.00013. eCollection 2020. Front Oncol. 2020. PMID: 32082995 Free PMC article. Review.
• The Osteosarcoma Microenvironment: A Complex But Targetable Ecosystem.
  Corre I, Verrecchia F, Crenn V, Redini F, Trichet V. Corre I, et al. Cells. 2020 Apr 15;9(4):976. doi: 10.3390/cells9040976. Cells. 2020. PMID: 32326444 Free PMC article. Review.

Cited by

• Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.
  Shaikh AB, Li F, Li M, He B, He X, Chen G, Guo B, Li D, Jiang F, Dang L, Zheng S, Liang C, Liu J, Lu C, Liu B, Lu J, Wang L, Lu A, Zhang G. Shaikh AB, et al. Int J Mol Sci. 2016 Apr 6;17(4):506. doi: 10.3390/ijms17040506. Int J Mol Sci. 2016. PMID: 27058531 Free PMC article. Review.
• The inhibitory effect of CTAB on human osteosarcoma through the PI3K/AKT signaling pathway.
  Da W, Tao L, Zhu Y. Da W, et al. Int J Oncol. 2021 Jul;59(1):42. doi: 10.3892/ijo.2021.5222. Epub 2021 May 20. Int J Oncol. 2021. PMID: 34013357 Free PMC article.
• miR-23a suppresses proliferation of osteosarcoma cells by targeting SATB1.
  Wang G, Li B, Fu Y, He M, Wang J, Shen P, Bai L. Wang G, et al. Tumour Biol. 2015 Jun;36(6):4715-21. doi: 10.1007/s13277-015-3120-0. Epub 2015 Jan 27. Tumour Biol. 2015. PMID: 25619478
• Silencing long intergenic non-protein coding RNA 00987 inhibits proliferation, migration, and invasion of osteosarcoma cells by sponging miR-376a-5p to regulate FNBP1 expression.
  Cao R, Shao J, Zhang W, Lin Y, Huang Z, Li Z. Cao R, et al. Discov Oncol. 2021 Jun 1;12(1):18. doi: 10.1007/s12672-021-00412-x. Discov Oncol. 2021. PMID: 35201476 Free PMC article.
• MiR-145 inhibits osteosarcoma cells proliferation and invasion by targeting ROCK1.
  Li E, Zhang J, Yuan T, Ma B. Li E, et al. Tumour Biol. 2014 Aug;35(8):7645-50. doi: 10.1007/s13277-014-2031-9. Epub 2014 May 7. Tumour Biol. 2014. PMID: 24801908

References

1. 1. Meyers P.A., Gorlick R. Osteosarcoma. Pediatr. Clin. North Am. 1997;44:973–989. doi: 10.1016/S0031-3955(05)70540-X. - DOI - PubMed
2. 1. Dorfman H.D., Czerniak B. Bone cancers. Cancer. 1995;75:203–210. doi: 10.1002/1097-0142(19950101)75:1+<203::AID-CNCR2820751308>3.0.CO;2-V. - DOI - PubMed
3. 1. Stiller C.A. International patterns of cancer incidence in adolescents. Cancer Treat. Rev. 2007;33:631–645. doi: 10.1016/j.ctrv.2007.01.001. - DOI - PubMed
4. 1. Coventry M.B., Dahlin D.C. Osteogenic sarcoma—A critical analysis of 430 cases. J. Bone Joint Surg. Am. 1957;39:741–757. - PubMed
5. 1. Marcove R.C., Mike V., Hajek J.V., Levin A.G., Hutter R.V. Osteogenic sarcoma under the age of twenty-one—A review of one hundred and forty-five operative cases. J. Bone Joint Surg. Am. 1970;52:411–423. - PubMed

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • MDPI
  • PubMed Central
  • White Rose Research Online

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations

• Miscellaneous

  • NCI CPTAC Assay Portal